Articles tagged "Viral therapy"

2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
2018 American Transplant Congress
Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C
C. Chan,¹ E. Agudelo,² J. Haydek,³ M. Hoteit,⁴ M. Laurito,⁵ J. Norvell,³ T. Schiano,⁶ N. Terrault,² E. Verna,⁵ A. Yang,¹ J. Levitsky.¹
¹Northwestern University, Chicago, IL; ²UCSF, San Francisco, CA; ³Emory University, Atl, GA; ⁴University of Pennsylvania, Philadelphia, PA; ⁵Columbia University, NY, NY; ⁶Mount Sinai, NY, NY.
Background and Aims:Interferon (IFN) treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in severe immune-mediated graft dysfunction (IGD). The occurrence…
2018 American Transplant Congress
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
D. Bley,¹ L. Sagardia,¹ R. Ford,² S. Todd.¹
¹Pharmacy, Emory University Hospital, Atlanta, GA; ²School of Medicine, Emory University, Atlanta, GA.
Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…
2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
R. Razonable, H. Amer, S. Mardini.
Mayo Clinic, Rochester, MN.
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…
2018 American Transplant Congress
Brincidofovir Was Used to Successfully Treat Adenovirus Infections in Solid Organ Transplant Recipients and Other Immunocompromised Patients
D. Florescu,¹ M. Grimley,² G. Papanicolaou,³ V. Prasad,⁴ E. Vainorius,⁵ G. Chittick,⁵ T. Brundage,⁵ G. Nichols.⁵
¹Univ Nebraska Med Center, Omaha; ²Cincinnati Children's Hosp Center, Cincinnati; ³Memorial-Sloan Kettering Cancer Center, New York; ⁴Pediatric BMT, Duke Univ Med Center, Durham, NC; ⁵Chimerix, Inc., Durham.
Background: Adenovirus (AdV) infections cause significant morbidity and mortality in immunocompromised patients. Brincidofovir (BCV) is an investigational antiviral drug with high in vitro potency against…
2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
A. Kwong,¹ A. Wall,² M. Melcher,² U. Wang,³ A. Ahmed,¹ K. Khush,³ A. Subramanian,³ J. Tan,³ P. Kwo.¹
¹Gastroenterology and Hepatology, Stanford University, Palo Alto, CA; ²Surgery, Stanford University, Palo Alto, CA; ³Stanford University, Palo Alto, CA.
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…
2018 American Transplant Congress
Early Adjunctive Treatment with Human Cytomegaly Virus (CMV) Immunoglobulin Increased CMV-Free Survival after Heart Transplantation
M. Barten,¹ C. Neumaier,¹ A. Bernhardt,¹ M. Rybczynski,² R. Plaetke,³ H. Reichenspurner.¹
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany; ³Institute of Medical Biometry and Epidemiology, University Hospital Eppendorf Hamburg, Hamburg, Germany.
Purpose: There is still an ongoing discussion whether a prophylactic or a preemptive therapy against cytomegalovirus (CMV) is superior to reduce the incidence of CMV…
2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
Y. Matsuoka,¹ K. Iwasaki,² Y. Miwa,² K. Horimi,¹ K. Uchida,² T. Kobayashi.¹
¹Renal Transplant Surgery, Aichi Medical University, Nagakute City, Aichi, Japan; ²Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute City, Aichi, Japan.
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…
2018 American Transplant Congress
Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis
G. Nance,¹ A. Serluco,¹ S. Deshpande,^2,1 R. Garro,^3,1 R. George,^3,1 M. Kelleman,³ R. Liverman.¹
¹Children's Healthcare of Atlanta, Atlanta, GA; ²Sibley Heart Center Cardiology, Atlanta, GA; ³Emory University, Atlanta, GA.
Objectives: Cytomegalovirus (CMV) is an opportunistic infection that can lead to significant complications post-transplant. Purpose of this study was to evaluate the use of valganciclovir…
2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
S. Albatati,¹ A. Sharma,² S. Gantt,¹ K. Haubrich,¹ A. Wright,¹ T. Blydt-Hansen.¹
¹University of British Columbia, Vancouver, Canada; ²University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…

1
2
3
…
7
Next Page »